Fully-funded MSc by Thesis in Biomedical Research
BEAT - A feasibility study to identify a biomarker of treatment frequency in neovascular age-related macular degeneration
Are you curious about research? Are you interested in ophthalmology, vascular biology, and precision medicine? Do you want to pursue a fully-funded MSc by Thesis in an environment supported by an excellent supervisory team?
If yes, this is the perfect opportunity for you. A fully funded MSc by Thesis funded by the Burgess Family and Friends. The funding covers fees at Home student rates, a UKRI-level stipend, and research costs.
This is a research project on the leading cause of vision loss and blindness in the UK , age-related macular degeneration (AMD). There are two types of AMD: dry-AMD and neovascular-AMD; also known as wet-AMD. Dry-AMD typically precedes wet-AMD and is associated with an increasing risk of conversion to wet-AMD over time. Approximately 40,000 people develop wet-AMD in the UK each year, with 25% developing wet-AMD in their second eye within 3 years.
As neovascularisation is the pathological driver of wet-AMD, inhibitors of VEGF are used as the standard treatment to slow disease progression. However, response to treatment and treatment intervals over time are variable amongst patients, which leads to increased burden to both patients and hospital eye services. The ability to predict a patient’s response to anti-VEGF treatment upon diagnosis of wet-AMD would help to manage patients’ expectations of their condition and help hospital eye services better manage patient care. For example, predicting those individuals who might require a high treatment frequency compared to those with a low treatment frequency to stabilise the disease.
This is exactly the challenge this project will aim to address. Under the supervision of Professor Gale, you will help with recruitment of a cohort including patients that require high or low frequency treatment and collect blood plasma. You will then analyse the collected samples for candidate vascular biomarkers in blood in the lab, under the supervision of Prof Lagos. By being a member of an interdisciplinary research team within the HYMS Experimental Medicine and Biomedicine group, you will gain experience in both designing and delivering a biomedical research study with tangible clinical benefits.
Closing Date: 14 April 2024
To find out more and apply, visit our MSc in Medical or Human Sciences (by thesis) page
Endogenous immune modulators in the pathophysiology of blood cancer
This fully-funded PhD project is ideal for candidates who have interest in immunology and blood malignancies. The focus will be on B-precursor acute lymphoblastic leukemia (B-ALL), the most common subtype of ALL in adults.
Using advanced cell co-culture models, organoids, cutting-edge real time imaging, immunological techniques and by analysing clinical samples, you will first explore how endogenous immune modulators shape multicellular interactions between stromal cells, immune cells, and cancer cells in order to harness malignancy development. Training will also be provided in mouse disease models including in vivo imaging. Importantly, the mechanisms explored here may be relevant to blood malignancies beyond the context of B-ALL. This project builds on and extends the existing critical mass in immunology and haematology in the York Biomedical Research Institute and Centre of Blood Research.
Closing Date: 28 March 2024
Find out more and apply on findaphd.com
Mapping Drug-Parasite-Host Interactions to Overcome Leishmaniasis Treatment Failures
Applications are invited for a 4-year PhD to join an innovative research program aiming to revolutionize drug treatment paradigms for the neglected tropical disease leishmaniasis.
Current leishmaniasis chemotherapies frequently fail due to suboptimal drug exposures at the infection site, allowing parasite subpopulations to survive and spread. The overarching goal is to investigate the role of drug distribution dynamics and Leishmania parasite dissemination in the emergence of clearance, persistence, and recurrent infection. This project will apply animal models and cutting-edge 3D liver and skin organotypic models mimicking visceral and cutaneous leishmaniasis microenvironments to map the spatiotemporal interplay between drug biodistribution, parasite burden, and host immune responses.
Closing Date: 28 March 2024
Find out more and apply on findaphd.com
Understanding immunological memory to malaria
An essential feature of the immune response to infectious pathogens is that it is enhanced by a second exposure. This outstanding mechanism of “remembering” previous exposures to a given pathogen, termed immunological memory, forms the basis for vaccination. Better understanding of the signals that regulate memory of B cells, white blood cells that produce antibodies, is key to develop improved vaccination regimes. However, studying the development of B cell memory is challenging as it requires identification and isolation of rare pathogen-specific B cells that exist often at very low frequencies. To circumvent this problem, we have generated novel genetic tools which allow tracking and isolating B cells specific to Plasmodium parasites (Perez-Mazliah et al., eLIFE, 2018), the pathogen that causes malaria. The successful candidate will combine this novel tool with cutting-edge transcriptomics, proteomics and transgenic mouse models to dissect novel mechanisms involved in the development of B cell memory.
Closing Date: 28 March 2024
Find out more and apply on findaphd.com
Understanding the interplay between acne treatment and the inflammasome
Acne is a very common, under researched area of high unmet clinical need and has a major impact on the patient’s quality of life. Isotretinoin remains the gold standard therapeutic for severe acne and while highly effective has important, potential physiological and psychological side effects and a mechanism of action that is poorly understood. This exciting fully-funded PhD project will explore the interplay between isotretinoin and innate immunity in acne as part of a fully funded, ongoing NIHR clinical trial running from 2023-2028, which aims to study a diverse patient cohort of acne patients receiving high and low doses of isotretinoin. The project will be supported by a supervisory team with expertise in skin biology, innate immunity and acne (Robinson, Boucher, Layton).
Closing Date: 28 March 2024
Find out more and apply on findaphd.com